Which company's drug information is mirikizumab?

Milikizumab (Mirikizumab) is an immunomodulatory drug developed by Eli Lilly and Company. Eli Lilly and Company was founded in 1876 and is headquartered in Indiana, USA. It is a world-renowned pharmaceutical company dedicated to improving the health of patients around the world through innovative medicines. Eli Lilly focuses on the fields of diabetes, cancer, immunology and neurology, and has launched many innovative drugs that have changed the lives of countless patients.

Mirikizumab (Mirikizumab) is a biological drug that targets immune-mediated diseases and is an IL-23 (interleukin-23) inhibitor. IL-23 is an important immune factor that participates in the inflammatory response of the immune system, especially playing a key role in chronic inflammatory bowel disease (IBD). By targeting the function of IL-23, Militizumab reduces the immune system's overreaction, thereby alleviating the symptoms of ulcerative colitis (UC) and Crohn's disease (CD), helping patients restore intestinal function and reduce pain and discomfort.

Militizumab was developed by Eli Lilly and Company after years of clinical research and development. It has been approved in many countries and regions and has demonstrated its excellent efficacy in clinical trials, especially in the treatment of refractory ulcerative colitis and Crohn's disease. The research and development of this drug is based on Eli Lilly's deep accumulation in the field of immunology, and its unique targeting mechanism has attracted widespread attention.

The launch of Milizumab not only strengthens Eli Lilly's competitiveness in the field of immunology, but also provides more treatment options for patients facing immune-mediated diseases around the world. With the deepening of clinical application, militizumab may be used in more immune-mediated diseases in the future, bringing good news to the majority of patients.

Keyword tags: Milikizumab,Mirikizumab, Eli Lilly and Company, Eli Lilly and Company, immunomodulation, ulcerative colitis, Crohn's disease

Reference materials:https://omvoh.lilly.com/